EyePoint Pharmaceuticals (STU:PV3) Short-Term Debt : €0.00 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Short-Term Debt?

EyePoint Pharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2023 was €0.00 Mil.

EyePoint Pharmaceuticals's annual Short-Term Debt increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€9.89 Mil) but then declined from Dec. 2022 (€9.89 Mil) to Dec. 2023 (€0.00 Mil).

EyePoint Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for EyePoint Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Short-Term Debt Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

9.89

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															9.89	4.95	-	-	-

EyePoint Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

EyePoint Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3) Headlines

No Headlines